Effect of first-line antituberculous treatment on vitamin D level in patients with pulmonary tuberculosis

Q4 Nursing
Deliang Lv, W. Tan, Jian Xu, Hui Yang, Jun-luan Mo, Yu-mei Zhu, Xiongshun Liang, X. Che, Qingfang Wu
{"title":"Effect of first-line antituberculous treatment on vitamin D level in patients with pulmonary tuberculosis","authors":"Deliang Lv, W. Tan, Jian Xu, Hui Yang, Jun-luan Mo, Yu-mei Zhu, Xiongshun Liang, X. Che, Qingfang Wu","doi":"10.3760/CMA.J.ISSN.1674-635X.2019.02.005","DOIUrl":null,"url":null,"abstract":"Objective \nTo explore the effect of first-line anti-tuberculosis treatment on vitamin D level in patients with pulmonary tuberculosis, and to master the changes of vitamin D level in the course of treatment, so as to provide a scientific basis for tuberculosis and nutrition health education in Shenzhen. \n \n \nMethods \nA total of 100 patients diagnosed as smear-positive pulmonary tuberculosis and receiving initial treatment in 2016 were enrolled and all the patients were treated with the standardized short-course chemotherapy regimens. The blood samples were extracted before treatment and at the ends of intensive and continuation phase. The 25-hydroxyvitamin D[25-(OH)D] concentrations were determined by chemiluminescence (CLIA)at each time point. The change of 25-(OH)D concentrations during anti-tuberculosis treatment was analyzed and the differences of vitamin D levels between different time points were identified. \n \n \nResults \n79(79.0%), 94(94.0%) and 96(96.0%)patients were found vitamin D deficiency before treatment and at the end of the intensive and continuation phases respectively, which showed an upward trend(χ2=15.543, P<0.001)and the 25-(OH)D concentrations were (15.74±6.54)ng/ml, (12.56±5.15)ng/ml, (11.51±4.28)ng/ml, respectively. During the whole course of treatment, the 25-(OH)D concentration decreased by 26.9% or (4.23±6.75)ng/ml(t=6.257, P<0.001), wherein it decreased (3.18±5.24)ng/ml in intensive phase (t=6.069, P<0.001) and (1.05±4.86)ng/ml in continuation phase (t=2.154, P=0.034). The former had a greater decreased value (t=2.836, P=0.006). There were 77 (77.0%) and 55 (55.0%) patients with 25-(OH)D concentration reduction in intensive and continuation phases respectively(χ2=9.680, P=0.003), of which 41 patients (41.0%) continued to decline. \n \n \nConclusion \nOnce anti-tuberculosis treatment is conducted, the vitamin D level will decrease rapidly in the intensive phase and continue decreasing throughout the course of treatment, which leads to a general lack of vitamin D in patients with primary pulmonary tuberculosis. First-line anti-tuberculosis drugs may be the main cause for vitamin D level reduction. Therefore, it is necessary for clinicians to strengthen vitamin D health education for each patient throughout the treatment period, especially for those at high risk of vitamin D deficiency who should be recommended adjuvant vitamin D supplementation therapy. \n \n \nKey words: \nPulmonary tuberculosis; Vitamin D deficiency; 25-hydroxyvitamin D; Anti-tuberculosis drug","PeriodicalId":9877,"journal":{"name":"中华临床营养杂志","volume":"27 1","pages":"90-95"},"PeriodicalIF":0.0000,"publicationDate":"2019-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华临床营养杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1674-635X.2019.02.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Nursing","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To explore the effect of first-line anti-tuberculosis treatment on vitamin D level in patients with pulmonary tuberculosis, and to master the changes of vitamin D level in the course of treatment, so as to provide a scientific basis for tuberculosis and nutrition health education in Shenzhen. Methods A total of 100 patients diagnosed as smear-positive pulmonary tuberculosis and receiving initial treatment in 2016 were enrolled and all the patients were treated with the standardized short-course chemotherapy regimens. The blood samples were extracted before treatment and at the ends of intensive and continuation phase. The 25-hydroxyvitamin D[25-(OH)D] concentrations were determined by chemiluminescence (CLIA)at each time point. The change of 25-(OH)D concentrations during anti-tuberculosis treatment was analyzed and the differences of vitamin D levels between different time points were identified. Results 79(79.0%), 94(94.0%) and 96(96.0%)patients were found vitamin D deficiency before treatment and at the end of the intensive and continuation phases respectively, which showed an upward trend(χ2=15.543, P<0.001)and the 25-(OH)D concentrations were (15.74±6.54)ng/ml, (12.56±5.15)ng/ml, (11.51±4.28)ng/ml, respectively. During the whole course of treatment, the 25-(OH)D concentration decreased by 26.9% or (4.23±6.75)ng/ml(t=6.257, P<0.001), wherein it decreased (3.18±5.24)ng/ml in intensive phase (t=6.069, P<0.001) and (1.05±4.86)ng/ml in continuation phase (t=2.154, P=0.034). The former had a greater decreased value (t=2.836, P=0.006). There were 77 (77.0%) and 55 (55.0%) patients with 25-(OH)D concentration reduction in intensive and continuation phases respectively(χ2=9.680, P=0.003), of which 41 patients (41.0%) continued to decline. Conclusion Once anti-tuberculosis treatment is conducted, the vitamin D level will decrease rapidly in the intensive phase and continue decreasing throughout the course of treatment, which leads to a general lack of vitamin D in patients with primary pulmonary tuberculosis. First-line anti-tuberculosis drugs may be the main cause for vitamin D level reduction. Therefore, it is necessary for clinicians to strengthen vitamin D health education for each patient throughout the treatment period, especially for those at high risk of vitamin D deficiency who should be recommended adjuvant vitamin D supplementation therapy. Key words: Pulmonary tuberculosis; Vitamin D deficiency; 25-hydroxyvitamin D; Anti-tuberculosis drug
一线抗结核治疗对肺结核患者维生素D水平的影响
目的探讨一线抗结核治疗对肺结核患者维生素D水平的影响,掌握治疗过程中维生素D水平的变化,为深圳市结核病及营养健康教育提供科学依据。方法选取2016年初治的痰阳性肺结核患者100例,均采用标准化短期化疗方案。在治疗前、强化期和继续期结束时采集血样。化学发光(CLIA)法测定各时间点25-羟基维生素D[25-(OH)D]浓度。分析抗结核治疗期间25-(OH)D浓度的变化,确定不同时间点维生素D水平的差异。结果治疗前、强化期和延续期结束时分别有79(79.0%)、94(94.0%)、96(96.0%)患者出现维生素D缺乏,且呈上升趋势(χ2=15.543, P<0.001), 25-(OH)D浓度分别为(15.74±6.54)ng/ml、(12.56±5.15)ng/ml、(11.51±4.28)ng/ml。在整个治疗过程中,25-(OH)D浓度降低了26.9%(4.23±6.75)ng/ml(t=6.257, P<0.001),其中强化期降低了(3.18±5.24)ng/ml (t=6.069, P<0.001),持续期降低了(1.05±4.86)ng/ml (t=2.154, P=0.034)。前者的下降值较大(t=2.836, P=0.006)。25-(OH)D浓度在强化期和延续期分别下降77例(77.0%)和55例(55.0%)(χ2=9.680, P=0.003),其中持续下降41例(41.0%)。结论一旦进行抗结核治疗,维生素D水平会在强化期迅速下降,并在整个治疗过程中持续下降,导致原发性肺结核患者普遍缺乏维生素D。一线抗结核药物可能是维生素D水平降低的主要原因。因此,临床医生有必要在整个治疗期间加强对每位患者的维生素D健康教育,特别是对维生素D缺乏的高危患者,应推荐辅助补充维生素D治疗。关键词:肺结核;维生素D缺乏;人体内25 -羟维生素D;抗结核药物
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
中华临床营养杂志
中华临床营养杂志 Nursing-Nutrition and Dietetics
CiteScore
0.20
自引率
0.00%
发文量
2282
期刊介绍: The Chinese Journal of Clinical Nutrition was founded in 1993. It is the first professional academic journal (bimonthly) in my country co-sponsored by the Chinese Medical Association and the Chinese Academy of Medical Sciences to disseminate information on clinical nutrition support, nutrient metabolism, the impact of nutrition support on outcomes and "cost-effectiveness", as well as translational medicine and nutrition research. It is also a professional journal of the Chinese Medical Association's Parenteral and Enteral Nutrition Branch. The purpose of the Chinese Journal of Clinical Nutrition is to promote the rapid dissemination of knowledge on nutrient metabolism and the rational application of parenteral and enteral nutrition, focusing on the combination of multidisciplinary and multi-regional field investigations and clinical research. It mainly reports on nutritional risk screening related to the indications of parenteral and enteral nutrition support, "cost-effectiveness" research on nutritional drugs, consensus on clinical nutrition, guidelines, expert reviews, randomized controlled studies, cohort studies, glycoprotein and other nutrient metabolism research, systematic evaluation of clinical research, evidence-based case reports, special reviews, case reports and clinical experience exchanges, etc., and has a special column on new technologies related to the field of clinical nutrition and their clinical applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信